
Tuesday, July 01, 2025 8:01:14 PM
Financials were solid. Growth all around - revenues, $4M debt paid off, working capital looking fantastic, continued investment in R&D, still only doing one shift and likely still have plenty of capacity in that single shift for more production.
Awesome to hear about how well Lisdex is doing right out of the gate. We didn't get any insight on Q1 revs and knowing we aren't having any major issues wirh API Q1 should be rocking with rich margins as he confirmed today. Other drugs launched continue to grow and gain market share. Nice to see a potential timeframe laid out with investment banker to kick off process once we get more Lisdex time under our belt to help with valuation.
Will Nasrat's (Chairman, CEO & 300M shareholder) share price he has in mind be close to what retail shareholders expect. He carries significant weight in that decision.
We wait - R&D partner & investment firm. Big bummer was to hear about wait on ANDA filing for anticoagulant until Q1 2026 for stabilization study. The end is coming into focus.
Can anyone expound why this ANDA would take significantly longer than others we've submitted? We always have to do stabilization studies for ANDAs.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/23/2025 11:05:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/16/2025 11:05:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2025 08:40:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2025 12:10:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2025 09:56:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2025 09:05:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 09:20:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/02/2024 09:35:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/18/2024 09:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2024 09:51:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 09:30:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/28/2024 09:23:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/23/2024 12:27:32 PM
- ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition • InvestorsHub NewsWire • 10/23/2024 12:03:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2024 08:47:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 08:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 09:16:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:53 PM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • CLDI • Jul 7, 2025 9:00 AM
VAYK Discloses More Insider Buying Approaching 15 Million • VAYK • Jul 2, 2025 10:37 AM
Patented, Groundbreaking Blockchain for Public Companies 'BlackStar Digital Trading PlatformTM' can Facilitate U.S. Registered Securities to Trade on Blockchain Without Tokens. • BEGI • Jul 1, 2025 12:54 PM
UC Asset (UCASU) Public Offering's Acquisition Target Reported Better Results • UCASU • Jul 1, 2025 9:15 AM
One World Products, Inc. Appoints William Rowland as Chief Financial Officer • OWPC • Jul 1, 2025 9:14 AM
Envirotech Begins Delivery of Bumble Bee Electric School Bus Units with First Three Texas Orders • EVTV • Jul 1, 2025 9:01 AM